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THE COST-EFFECTIVENESS OFVARENICLINE IN SMOKING
CESSATION IN DENMARK
Poulsen PB1, Dollerup J1, Keiding H2
1Pﬁzer Denmark, Ballerup, Denmark, 2University of Copenhagen,
Copenhagen, Denmark
OBJECTIVES: From a Danish perspective to analyse the incre-
mental cost-effectiveness of the pharmacological smoking cessa-
tion therapy including counselling using varenicline (Champix®)
compared with bupropion SR (Zyban®), nicotine replacement
therapy (NRT) or smoking cessation courses (group based coun-
seling). METHODS: A Markov model was developed using a
hypothetical Danish cohort of smokers who made a single quit
attempt (cycle length 1 year). The direct costs of smoking cessa-
tion and treatment of smoking-related diseases (COPD, lung
cancer, CHD, stroke and asthma exacerbations) were included
(2006-prices). Future costs were discounted at 5%. The incre-
mental cost-effectiveness was calculated as costs per quitter and
costs per QALYs gained. The evidence for quit rates included
head-to-head trials for varenicline versus bupropion, a Cochrane
review of NRT (Stead et al., 2008) and a Danish cohort study of
smoking cessation courses (Kjaer et al., 2007). The time horizons
applied were 20-year and lifetime. RESULTS: Modelling results
revealed that varenicline resulted in more quitters and fewer
cases of smoking-related diseases. In a 20-year time horizon
(lifetime) cumulative QALYs gained using varenicline were 1,04
(4237) compared with smoking cessation courses, and up to
2517 (5600) QALYs compared with NRT. The costs per addi-
tional quitter using varenicline instead of bupropion were
DKK3060 (20-year), whereas varenicline was cost-saving com-
pared with NRT and smoking cessation courses. With a lifetime
perspective varenicline was always a cost-saving option in terms
of cost per quitter. Resulting in more QALYs and fewer costs
varenicline dominated the other alternatives, when lifetime was
considered. With a 20-year time horizon, the costs per QALY
gained for varenicline versus bupropion were DKK30,272, but
varenicline still dominated NRT and smoking cessation courses.
CONCLUSIONS: This cost-effectiveness analysis conﬁrms that
varenicline is a cost-effective strategy for smoking cessation in
Denmark. This ﬁnding is in accordance with results found in
Sweden and The Netherlands.
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OBJECTIVES: To estimate the direct and indirect costs of aller-
gic rhinitis (AR) in pediatric patients from the perspective of
patient’s family. METHODS: 195 patients (children/adolescents)
from a third-level public pediatric hospital that do not belong
to social security system were included in this retrospective,
cross-sectional cost-of-illness study. Information of demographic
characteristics, frequency and severity of illness, consultations,
diagnostic tests, out-of-pocket-expenditure for medication,
transportation, food and house refurbishment as well as absence
from work of caregivers and school absenteeism of patients was
collected with a standardized questionnaire. Additionally, the
corresponding clinical records were reviewed to conﬁrm the pre-
scribed medications and the sickness evolution. Country level
costs were obtained applying recent prevalence estimates of AR.
RESULTS: The average annual costs per children are €264.96.
Assuming that AR prevalence in this age group ranges from
18.5% to 42.1%, the costs of AR in Mexico range from €623.52
to €1,418.92 millions annually. For adolescents the average
annual costs per patient are €278.81, assuming AR prevalence
goes from 21.3% to 41.3%, the country level costs range from
€640.61 to €1242.11 millions annually. For both age groups
direct costs are responsible for 97.4% and 98.7% of the expen-
ditures respectively, being medications the main cost driver.
Antihistamines represent 38.1% and 33.6% of the medication
costs for children and adolescents respectively. House refurbish-
ment was the most relevant cost factor within nonmedical direct
costs, however, only 30% of the caregivers mentioned had had
this type of expenditure. There was no difference in costs accord-
ing to illness severity, although the school absenteeism was
twofold in children. CONCLUSIONS: The economic burden of
AR in Mexico is important since 50% of health expenditure
comes from out-of-pocket. Nevertheless these results could
underestimate the real cost of illness because parents not neces-
sarily accomplish the recommendations of pediatricians related
to medications and house refurbishment.
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WITH MILD COPD—RESULTS FROMTHE KORA F3 STUDY
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD)
is a common chronic condition that has many systemic effects
beyond pulmonary problems alone.Our objectivewas to calculate
direct medical excess costs of COPD. METHODS: Data from the
population-based KORA survey conducted in the region of Augs-
burg in 2004/05 were used to calculate excess costs of COPD.
Data were available for 200 subjects with and 2984 subjects
without COPD. Diagnosis of COPD was based on questions on
chronic cough for more than three months a year. Direct medical
costs were calculated based on self-reported resource use with
regard to physician visits, hospital stays, rehabilitation and drug
consumption. To adjust for age differences between participants
with and without COPD, controls that matched subjects with
COPD in terms of age and sex were randomly sampled from those
without COPD. To value utilization, recommended national unit
costs were inﬂated to 2005 price levels. RESULTS: Costs were
signiﬁcantly higher in subjects with COPD with regard to total
costs, drugs and physician visits (p < 0.0001), but not for hospital
stays. With these mild cases, no excess costs of rehabilitation were
observed. Preliminary analyses showed total direct medical excess
costs for COPD of about €900 per year, the largest contribution
coming from drug consumption (€600). CONCLUSIONS: Total
direct medical costs are higher for subjects with COPD, and two
thirds of these excess costs are due to the use of medications.
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THE HOSPITALIZATION COST OF PATIENTS WITH CHRONIC
OBSTRUCTIVE PULMONARY DISEASE (COPD) INTHE
UNIVERSITY HOSPITAL OF ALEXANDROUPOLIS, GREECE
Hatzikou M1, Ravikalis V2, Steiropoulos P3, Geitona M1, Bouros D3
1University of Thessaly,Volos, Greece, 2University of Alexandroupolis,
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INTRODUCTION: Patients with COPD consume considerable
health care resources due to their lung disease and frequent
comorbidities.OBJECTIVES:To estimate the hospitalisation cost
of patients suffering fromCOPD in the department of pneumonol-
ogy of the university hospital of Alexandroupolis, Greece.
METHODS:The study sample consisted of all the patients, 142 in
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